Dr. Goldberg on FDA-Approved Agents for Patients With AML

Video

In Partnership With:

Stuart L. Goldberg, MD, hematologist, John Theurer Cancer Center, discusses the use of 4 FDA-approved agents for patients with acute myeloid leukemia (AML) with varying genetic alterations.

Stuart L. Goldberg, MD, hematologist, John Theurer Cancer Center, discusses the use of 4 FDA-approved agents for patients with acute myeloid leukemia (AML) with varying genetic alterations.

AML is an extremely complex disease at a genetic and chromosomal level. Traditionally, chromosomes have been used to determine whether a patient should get a bone marrow transplant, or whether they should go to consolidation chemotherapy for risk stratification. The introduction of molecular testing has helped determine which targeted therapy to give.

The history of the patient, is critical in determining which agent to give. CPX-351 (Vyxeos) may be the best option for a patient who has a history of myelodysplastic changes or second treatment. If a patient has a genetic alteration of FLT3, an upfront FLT3 inhibitor like midostaurin (Rydapt) may be better suited for the patient. In the second-line setting, some of the experimental agents may be considered. An IDH mutation may warrant the use of an IDH2 inhibitor, says Goldberg. If the patient has a core-binding factor, gemtuzumab ozogamicin (Mylotarg) may play a role.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute